[Estimation of blood pressure, selected biochemical parameters and indices of left ventricular heart function in patients with mild or moderate essential hypertension treated with potassium losartan].
This study was conducted in 19 patients with mild or moderate essential hypertension randomised open trial to evaluate the influence of potassium losartan dosed 50 mg per day on blood pressure, metabolic processes and left ventricular heart function. The following intervals of examination were accepted-at entry (before therapy with losartan) and then after 10 days; after 30 days and after 60 days of treatment. Mean values of arterial blood pressure and heart rate measured by conventional technics and obtained from 24-hour ambulatory monitoring data, biochemical results (serum levels of glucose, uric acid, creatinine, sodium, potassium, total cholesterol, HDL-cholesterol, LDL-cholesterol, triglycerides, bilirubin and serum activity of aminotransferases) and selected indices of left ventricular heart function were evaluated as intragroup differences using Student's paired t test. Afterwards the body mass index was compared. Statistically significant decrease of systolic arterial pressure after 60 days of therapy was revealed and it concerned both diurnal period and sleep time and during whole 24 hours. During treatment with losartan mean creatinine serum level was increased and the serum level of bilirubin was decreased in serum after 10 days of therapy. No significant changes were noted in any other laboratory parameters. After 30 and 60 days of treatment with potassium losartan thickness of interventricular septum end-diastole (IVS-D) diminished and E/A ratio (transmitral flow during early ventricular diastole to peak velocity of late filling) augmented statistically significantly after 30 days of treatment. In addition body mass index was increased after 10 days of therapy with losartan when compared with this index at the entry. This study confirmed profitable antihypertensive losartan effect as significant decrease of systolic blood pressure and demonstrated improve diastolic function of left ventricle during therapy in patients with mild or moderate essential hypertension.
Hrycek
A
A
Klinika Chorób Wewnetrznych i Farmakologii Klinicznej Sl. AM w Katowicach.
Badowski
R
R
Scieszka
J
J
Haczkiewicz
P
P
Hefczyc
J
J
Cieślik
P
P
D000328:Adult; D000368:Aged; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001663:Bilirubin / Q000097:blood; D001786:Blood Glucose / Q000378:metabolism; D001794:Blood Pressure / Q000187:drug effects*; D018660:Blood Pressure Monitoring, Ambulatory; D002784:Cholesterol / Q000097:blood; D005260:Female; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000188:drug therapy*; D019808:Losartan / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011188:Potassium / Q000097:blood; D012964:Sodium / Q000097:blood; D013997:Time Factors; D016896:Treatment Outcome; D014280:Triglycerides / Q000097:blood; D014527:Uric Acid / Q000097:blood; D016277:Ventricular Function, Left / Q000187:drug effects*
D000889:Anti-Arrhythmia Agents; D000959:Antihypertensive Agents; D001786:Blood Glucose; D014280:Triglycerides; D014527:Uric Acid; D002784:Cholesterol; D012964:Sodium; D019808:Losartan; D001663:Bilirubin; D011188:Potassium